Clinical Trials

NCT03604991 | SUSPENDED | PHASE2/PHASE3
278 participants

Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-29
Start Date:
2019-05-03
Completion:
2026-12-31
Conditions
  • Clinical Stage II Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Clinical Stage III Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Esophageal Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
  • RADIATION
No Results Yet
NCT03595124 | ACTIVE_NOT_RECRUITING | PHASE2
15 participants

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-29
Start Date:
2019-01-08
Completion:
2024-09-30
Conditions
  • Metastatic Renal Cell Carcinoma
  • Stage III Renal Cell Cancer AJCC v8
  • Stage IV Renal Cell Cancer AJCC v8
  • TFE3-Rearranged Renal Cell Carcinoma
  • Unresectable Renal Cell Carcinoma
Interventions
  • DRUG
  • BIOLOGICAL
NCT03590821 | NOT_YET_RECRUITING | EARLY_PHASE1
60 participants

Timed Aspirin Chronobiome Study

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-29
Start Date:
2027-12-31
Completion:
2028-01-31
Conditions
  • Healthy
Interventions
  • DRUG
No Results Yet
NCT03504644 | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2
40 participants

Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-29
Start Date:
2018-08-13
Completion:
2025-07-22
Conditions
  • Recurrent Adult Lymphoblastic Lymphoma
  • Recurrent B Acute Lymphoblastic Leukemia
  • Recurrent B Lymphoblastic Lymphoma
  • Recurrent T Acute Lymphoblastic Leukemia
  • Recurrent T Lymphoblastic Lymphoma
  • Refractory B Acute Lymphoblastic Leukemia
  • Refractory B Lymphoblastic Lymphoma
  • Refractory T Acute Lymphoblastic Leukemia
  • Refractory T Lymphoblastic Lymphoma
Interventions
  • PROCEDURE
  • DRUG
NCT03412877 | RECRUITING | PHASE2
285 participants

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-29
Start Date:
2018-09-06
Completion:
2027-03-23
Conditions
  • Endocrine Tumors
  • Non-Small Cell Lung Cancer
  • Ovarian Cancer
  • Breast Cancer
  • Gastrointestinal/Genitourinary Cancers
  • Neuroendocrine Tumors
  • Multiple Myeloma
Interventions
  • DRUG
  • BIOLOGICAL
No Results Yet
NCT03375320 | ACTIVE_NOT_RECRUITING | PHASE3
298 participants

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-29
Start Date:
2018-10-26
Completion:
2023-08-23
Conditions
  • Functioning Pancreatic Neuroendocrine Tumor
  • Intermediate Grade Lung Neuroendocrine Neoplasm
  • Locally Advanced Digestive System Neuroendocrine Neoplasm
  • Locally Advanced Digestive System Neuroendocrine Tumor G1
  • Locally Advanced Lung Neuroendocrine Neoplasm
  • Locally Advanced Pancreatic Neuroendocrine Tumor
  • Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm
  • Low Grade Lung Neuroendocrine Neoplasm
  • Lung Neuroendocrine Tumor
  • Lung Neuroendocrine Tumor G2
  • Metastatic Digestive System Neuroendocrine Neoplasm
  • Metastatic Digestive System Neuroendocrine Tumor G1
  • Metastatic Lung Neuroendocrine Neoplasm
  • Metastatic Lung Neuroendocrine Tumor
  • Metastatic Pancreatic Neuroendocrine Neoplasm
  • Metastatic Pancreatic Neuroendocrine Tumor
  • Metastatic Thymus Neuroendocrine Neoplasm
  • Neuroendocrine Neoplasm
  • Neuroendocrine Tumor
  • Neuroendocrine Tumor G2
  • Non-Functioning Pancreatic Neuroendocrine Tumor
  • Pancreatic Serotonin-Producing Neuroendocrine Tumor
  • Thymus Neuroendocrine Tumor
  • Unresectable Digestive System Neuroendocrine Neoplasm
  • Unresectable Digestive System Neuroendocrine Tumor G1
  • Unresectable Lung Neuroendocrine Neoplasm
  • Unresectable Pancreatic Neuroendocrine Neoplasm
  • Unresectable Thymus Neuroendocrine Neoplasm
Interventions
  • PROCEDURE
  • DRUG
  • OTHER
NCT03348631 | ACTIVE_NOT_RECRUITING | PHASE2
62 participants

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-29
Start Date:
2019-05-01
Completion:
2023-07-28
Conditions
  • Recurrent Endometrial Endometrioid Adenocarcinoma
  • Recurrent Malignant Uterine Corpus Neoplasm
  • Recurrent Ovarian Carcinoma
  • Recurrent Ovarian Clear Cell Adenocarcinoma
  • Recurrent Ovarian Endometrioid Adenocarcinoma
Interventions
  • PROCEDURE
  • DRUG
NCT03289962 | COMPLETED | PHASE1
273 participants

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-29
Start Date:
2017-12-20
Completion:
2025-07-01
Conditions
  • Melanoma
  • Non-Small Cell Lung Cancer
  • Bladder Cancer
  • Colorectal Cancer
  • Triple Negative Breast Cancer
  • Renal Cancer
  • Head and Neck Cancer
  • Other Solid Cancers
Interventions
  • DRUG
No Results Yet
NCT03269669 | ACTIVE_NOT_RECRUITING | PHASE2
73 participants

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-29
Start Date:
2018-01-23
Completion:
2025-12-31
Conditions
  • Grade 1 Follicular Lymphoma
  • Grade 2 Follicular Lymphoma
  • Grade 3a Follicular Lymphoma
  • Recurrent Follicular Lymphoma
  • Refractory Follicular Lymphoma
Interventions
  • DRUG
  • PROCEDURE
  • BIOLOGICAL
No Results Yet
NCT03251989 | COMPLETED
326 participants

Rare CNS Tumors Outcomes &Risk

Study Type:
OBSERVATIONAL
Last Updated:
2026-05-29
Start Date:
2017-08-21
Completion:
2025-05-06
Conditions
  • PNET
  • Primary CNS Sarcoma
  • High Grade Meningioma
  • Ependymoma
  • Medulloblastoma
No Results Yet
NCT03244384 | ACTIVE_NOT_RECRUITING | PHASE3
739 participants

Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-29
Start Date:
2017-11-03
Completion:
2026-06-01
Conditions
  • Localized Renal Pelvis and Ureter Urothelial Carcinoma
  • Locally Advanced Bladder Urothelial Carcinoma
  • Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma
  • Locally Advanced Ureter Urothelial Carcinoma
  • Locally Advanced Urothelial Carcinoma
  • Stage II Bladder Urothelial Carcinoma AJCC v6 and v7
  • Stage II Renal Pelvis and Ureter Cancer AJCC v7
  • Stage II Ureter Cancer AJCC v7
  • Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
  • Stage III Renal Pelvis and Ureter Cancer AJCC v7
  • Stage III Ureter Cancer AJCC v7
Interventions
  • PROCEDURE
  • OTHER
  • BIOLOGICAL
No Results Yet
NCT03228537 | ACTIVE_NOT_RECRUITING | PHASE1
28 participants

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-29
Start Date:
2018-07-16
Completion:
2022-10-01
Conditions
  • Biphasic Mesothelioma
  • Epithelioid Mesothelioma
  • Stage I Pleural Diffuse Malignant Mesothelioma AJCC v7
  • Stage IA Pleural Diffuse Malignant Mesothelioma AJCC v7
  • Stage IB Pleural Diffuse Malignant Mesothelioma AJCC v7
  • Stage II Pleural Diffuse Malignant Mesothelioma AJCC v7
  • Stage III Pleural Diffuse Malignant Mesothelioma AJCC v7
Interventions
  • DRUG
  • PROCEDURE
  • RADIATION
Previous
Sorted by latest updates
Next
Showing 40 trials per page